# Japanese Encephalitis Vaccine

Type: Product

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/japanese-encephalitis-vaccine
Canonical HTML page: https://getbiobrief.com/entity/japanese-encephalitis-vaccine

## Recent coverage (1 stories)

### Meiji Licenses JE Vaccine Tech to Serum Institute for 2027 Filing
2026-08-24 09:41:38 · Sentiment: Positive · Impact: 6/10 · Sources: 2

Meiji Seika Pharma will transfer manufacturing technology for its Japanese encephalitis vaccine, developed and marketed by KM Biologics in Japan, to Serum Institute of India. SII engineers have already visited Japan, and the Indian firm expects to file for regulatory approval as early as 2027.
Full story: https://getbiobrief.com/story/meiji-serum-je-vaccine-tech-transfer-bio

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.